Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SEC Charges San Diego Lawyers and Others in an International Market Manipulation Scheme
http://www.sec.gov/news/press/2013/2013-39.htm
"The SEC is seeking to have the defendants return their allegedly ill-gotten gains, with interest, and to bar Carrillo, Huettel, de Beer, John Kirk, Benjamin Kirk, Boyle, and Hinton from participating in penny stock offerings and from serving as public company officers or directors. The SEC is seeking civil monetary penalties from the attorneys, their law firm, and from de Beer."
Not sure what this means for those that lost money but at least they're not getting away with it.
I doubt if ASC or SEC will ever do anything. I checked ASC site today and still no pending hearings for Skymark, et al.
Maybe they have bigger fish to fry.
Fact is, in the world of promoters, Skymark wasn't even that great. They only got TSHO to a market cap of about $37,000,000 back in Feb 2010 at it's peak.
The biggest promoters out there have gotten complete scam companies, with no real products or legit biz partners to a market cap of over $1,000,000,000 for some promo's I've watched (but not invested in) in recent months. (BTW: to anybody reading this, avoid those pure promo plays at all costs unless you want to lose your shirt).
Lesson learned indeed. It's odd to me that this thing still trades. Well, at least periodically it still trades.
Unlike other penny stocks out there TSHO had enougth truth behind them to make it believable (real products, some sales starting, real business partners). Remember the Cesari Direct business partner. That was a big one for me.
No idea what the future holds here. Will be interesting to see.
.0001 and now "grey markets" for TSHO - Luniel, you must be proud
I think I know what's next:
Solar powered squeegees
It'll be interesting to see what's next.
TSHO's been dark for over 1 year now.
Certainly ASC delayed whatever their next step is. We'll have to wait and see.
That post is old info from last year. If you go up one level in the ASC site it says "adjourned indefinitely on application by parties"
So, in one link it looks like the ASC had proposed some dates for ASC, TSHO, and PBEC to have a hearing, but then the parties couldn't agree to a date so adjourned infefinitely?
http://www.albertasecurities.com/statusofproceedings/Pages/default.aspx
There's not even anything pending on the schedule.
Been almost 1 year since the last communication from TSHO.
That’s a long hibernation. I wonder when Luniel is going to come out from under that rock.
In the meantime, “squeegee scrubber combo’s” have been showing up at many retailers, including Home Depot and Walmart. Some even have "ultimate" in their name. Ettore, for example, has an "Ultimate Window Cleaner Squeegee". Branding looks similar to the U/S.
TSHO either (1) completely missed the boat/doesn't care or (2) sold the rights, or (3) is working on something but I'm not holding my breath
NEWS OUT: Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire via COMTEX/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures (MILV.pk), has entered into the $8.4 billion market chronic obstructive pulmonary disease market (COPD) with the completed acquisition of a ground breaking Breathing Formula. This all natural, non-synthetic, medicine was developed for the treatment of COPD, the two most common forms of which are Emphysema and Chronic Bronchitis. We believe that there is no other product currently available that can achieve the same results.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.
The Pharmacor 2010 findings from the topic titled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the USA, France, Germany, Italy, Spain, UK and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade. Although two maintenance therapies currently dominate the COPD market--GlaxoSmithKline's Advair/Seretide/Adoair and Boehringer Ingelheim/Pfizer's Spiriva--the near-term market will become fractured owing to the launch of new agents and generic erosion of key brands.
COPD is the fastest growing cause of death in the world's advanced economies. Such is the scale of the disease that the World Health Organization predicts it will be the third leading cause of death in the developed world by the year 2020 - faster growing than lung cancer, heart disease and stroke. The disease has reached epidemic proportions. It is estimated that up to 600 million people may suffer from COPD worldwide.
Robert deZanger, CEO of Nature's Bioceuticals states, "We are excited to roll out our COPD formula. The market for our product is immense and the need is great. People afflicted with COPD have been prescribed repurposed asthma medicines to help them breathe. Our product should provide "natural relief", without the harmful side effects, to millions of people with chronic breathing problems."
Nature's Bioceuticals management is currently determining whether to go through the time and expense of filing an Investigational New Drug (IND) Application and New Drug Application with the FDA for approval as a drug or to market the Formula as a nutritional supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). If the formula is marketed under DSHEA the company will not be able to make any claims about the product treating, preventing or curing COPD or any disease.
If the product is marketed under DSHEA we expect revenues to exceed $12 million year one during ramp up and $40 million year two as we gain market share.
About Nature's Bioceuticals;
Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.
Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"
In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
Media Contact:
Financial Insight
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com
SOURCE Nature's Bioceuticals
Copyright (C) 2011 PR Newswire. All rights reserved
It's one thing to be pessimistic, but it's another thing to be living in perpetual misery.
Nobody is predicting they'll be added to the S&P 500 anytime soon.
By the way, you never answered my question about how many shares you are up to in this thing?
Glad to see the Kirk's and Boyle being charged.
The sooner this investigation is finished and these P&D'ers face justice, the sooner TSHO can raise their next round of financing and get back to the business of building shareholder value.
When is this thing going to come out of hibernation?
A Window into Potential Future Regeneca Products:
http://www.trademarkia.com/company-regeneca-international-inc-2862710-page-1-2
I don't have the familiarity with Nicosia's track record that you and others have on this board, but as long has he keeps surrounding himself with people smarter and more experienced that he, than his track record becomes less and less relevant. Douglas Platt's background is an example:
"With 30 years industry experience, Mr. Platt has managed an international consulting group for more than 20 years that provides a network of professional associates for the dietary supplement and pharmaceutical industries responsible for the coordination and implementation of the QA systems, QC procedures, and current Good Manufacturing Practice (cGMP) compliance. During his management tenure with companies such as Baxter, Alpha Therapeutics (now Grifols USA), TEVA of Israel, and Chiron (now Novartis), Mr. Platt has been actively involved with the PDA, ISPE, and NPTA while continuing to serve as a lecturer in the Pharmaceutical Engineering Certificate Program at California State University Fullerton. In addition to a BS degree in Psychology, Mr. Platt has earned a certificate in Pharmacy at Fort Sam Houston Medical School, a certificate in Bio-containment Technology at Johns Hopkins University, and a MS in Pharmaceutical Technology at the University of London."
There's not 100,000,000 o/s, it's about 25,000,000 o/s. Any significant dilution since then would need to be announced, hopefully along with the next year's cash flow needs.
On the previously referenced site, both the o/s and a/s are wrong which validates for me that the data there is unreliable. Below is the most recent breakdown from the 11/30 quarterly - hope this helps:
Item 2. Shares Outstanding
As of November 30, 2010 the Company has authorized 500,000,000 common shares, par value $.0001. At November
30, 2010 there were 24,707,311 common shares issued and outstanding.
Of the shares outstanding, 21,571,457 were freely trading.
Ethos Environmental Appoints Douglas Platt as Sr. Director of Quality Systems and Regulatory Compliance
Looks to have good credentials and clearly a needed appointment.
http://www.marketwatch.com/story/ethos-environmental-appoints-douglas-platt-as-sr-director-of-quality-systems-and-regulatory-compliance-2011-05-03?siteid=bigcharts&dist=bigcharts
How many shares are you up to?
After that news yesterday, still ended up on 2nd largest volume of year.
ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ
When are we going to get some news here?
Coming up on 3 months since they lost their G/S...
It'll be interesting to hear what they say about this on today's conference call.
Dissapointing for sure that Sulfoaildenafil, an FDA aproved ED treatment drug was found in certain lots of their all natural product.
I can't listen to the call but maybe it'll be recorded.
http://www.marketwatch.com/story/ethos-environmental-announces-market-update-conference-call-2011-04-29?siteid=bigcharts&dist=bigcharts
How are sales coming along?
Ethos Environmental Announces Expansion to New Office Location Due to Growth
http://www.marketwatch.com/story/ethos-environmental-announces-expansion-to-new-office-location-due-to-growth-2011-04-21?siteid=bigcharts&dist=bigcharts
I agree 100%.
My guess is they've been planning for moving beyond G/S aka W/P since when Paul Curhan came on board last July.
It's just taking longer than I thought because the ASC thing slows them down. But in the long run it may make them stronger (and wiser) and allows us shareholders to increase our position.
By now, the Rat is probably one of the largest shareholders and will come back with a new alias later this year.
NextStage1
Merger? Acquisition? Dilution? Loan?
What are people's opinions on what's next? I have to think they had a plan when they dropped G/S. It's been very quiet in TSHO land.
The FDA approval process was just mentioned in the video as a possibility. It's not a requirement for this product to succeed or sell. It's already selling and seems to be selling at a nice growth rate based on what a couple other posters here have written.
You are right that gaining a meaningful percent of the market for ED products will take time. But it is a $20,000,000,000 market "today" and that market will only grow over time. Wouldn't take much of a share of the ED market to result in nice growth for this stock.
The Regeneca Conference Videos from earlier this year sold me on the massive potential for this product. And this is just their first product:
A few weeks back I watched the videos on http://regenecafivestar.com/
The 1st and 3rd videos in particular were compelling and gave credibility that I was looking for. Plus, it helped me realize that this isn't a male enhancement product (as I originally thought), but an all natural over the counter ED product.
The fact that they're going to eventually have this thing FDA tested for it's ED efficiacy is huge. Shows they know it's not snakeoil and actually works.
If we get just 5% of the $20 Billion market for ED products this will be tremendous. According to the doctor in the 3rd video (gentlemen who went to Harvard) it's 100% natural, basically no side effects, costs a fraction of Viagra/Levitra/Cialis, plus it lasts 72 hours (much longer than the others), and you don't have to go through embarassing Dr. appointments to get it. This could take a massive slice out of the $20 Billion ED market.
Plus, the $20B market becomes an $80B market if there's an all-natural product that's as effective as Viagra, with no side effects, for 1/2 the cost. Another point this doctor made in the video.
Numbers mentioned here by others will need to be confirmed by financials, which I believe need to be out by May 15.
According to posters on this board they had $4MM sales in Jan/Feb. Then another $3MM in March(to get to $7MM sales by end of 1Q 2011). That's a strong month-to-month growth rate.
IF margins are 25% or so, there's plenty of room for shareholders to make money.
I won't blindly hold either and need to see confirmation of results in their financials.
1.1MM shares traded after market. Brought total up to 3.4MM shares traded today.
Thanks for the info. Nice margins.
Volume today is highest since the date the Regeneca / ETEV merger announced. Still over an hour to go.
$3MM more sales in March, after a combined $4MM in Jan-Feb according to your posts. Seems like sales are growing nicely. Thanks for the update.
Any sense of margins? I believe you said in a prior post that pills sold for $16.99 each, and cost a couple bucks. But MLM'ers have to be paid too. Are 25% margins a reasonable assumption for ETEV shareholders? Higher? Lower?
Indeed. Nice volume building over last couple of days.
Agreed. Tradeshow needs to launch successful products.
That's the only way Shareholders get money back. No legal proceeding, whether ASC or other, will result in any material benefit to shareholders (present or past).
Thankfully the selling seems to have resolved itself.
According to 3/1/11 8-K: "Mitch Huhem was issued Fifty Million (50,000,000) shares of Common Stock of the Company, which shares shall be fully paid, validly issued and non-assessable restricted stock."
It was restricted common stock. So he can't sell it in the near term.
There are a lot of issued common shares but that's why the want to eventually do the reverse split.
Mitch Huhem and others wouldn't be accepting stock as part of their agreement to work with Regeneca if they didn't believe in the potential of the "stock" of the company. My thoughts anyway.
RE: Post #974 by ElderWolf which was deleted:
I'm not sure why that one was deleted, but you said:
My conspiracy theory is this:
Luniel was a puppet manipulated by the Kirk family and Skymark. He doesn't have background in the markets, and I think Luniel got played big time by Skymark and Kirks.
Unfortunately, the only way investors & former Skymark subscribers get their money back is if these companies succeed. As you're right that any fines will likely be minimal.
That's the same report as the one from Aug/Sept last year. They just re-posted it.
I don't think we know yet who paid the $5,000 / month that they allege. It wasn't Tradeshow because it clearly says it was a thrid party. Wouldn't it be more likely that it was an associated Kirk family member that was the third party described?
PS: the $20B market becomes an $80B market if there's an all-natural product that's as effective as Viagra, with no side effects, for 1/2 the cost.
Another point the 2nd Doctor mentioned that I forgot to mention.
Thanks for the info. Odd that no lawyer from TSHO was there. PBEC has much more cash than TSHO, though TSHO has more of a pipeline (at least they did). So maybe they just decided to have 1 company send a lawyer, since the companies are interrelated in this ASC thing.
As PBEC goes so will TSHO go in my opinion with the ASC thing.
I watched the videos on http://regenecafivestar.com/
They were really compelling. I really felt the 1st and 3rd video in particular were compelling and gave credibility that I was looking for.
The fact that they're even going to eventually have this thing FDA tested for it's ED efficiacy is huge. Shows they know it's not snakeoil and actually works.
If we get just 5% of the $20 Billion market for ED products this will be tremendous. According to the 2nd doctor (Asian guy from Harvard who seemed more credible to me than Italian Doctor) it's 100% natural, basically no side effects, costs a fraction of Viagra/Levitra/Cialis, plus it lasts 72 hours (much longer than the others), and you don't have to go through embarassing Dr. appointments to get it. This could take a massive slice out of the $20 Billion ED market.
Do you know the timing of the other products?